Skip to NavigationSkip to content

AstraZeneca fights generic Nexium bid

Published on 25/11/05 at 11:20am

AstraZeneca has filed a lawsuit in the US courts to block the launch of a generic version of Nexium.

The ulcer treatment is AstraZeneca's biggest selling brand, and is expected to earn the company around $4.5 billion this year - revenue the company is determined to protect.

Indian generics company Ranbaxy wants to launch its own version of the drug in the US, but AstraZeneca says it infringes six separate patents, which could provide it with market exclusivity up to 2019.

AstraZeneca recently filed a lawsuit to tackle a separate generic challenge to another of its leading brands, schizophrenia blockbuster Seroquel.

Related articles:

Oxford and GSK to collaborate on cancer research in India 

Friday , November 18, 2005




Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches